Heidelberg Pharma AG
F:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Heidelberg Pharma AG
F:HPHA
|
DE |
|
Brunello Cucinelli SpA
MIL:BC
|
IT |
|
Haldex AB
F:HLV
|
SE |
|
Catana Group SA
PAR:ALCAT
|
FR |
|
I
|
Innovative Industrial Properties Inc
SWB:1IK
|
US |
|
D
|
Danaher Corp
SWB:DAP
|
US |
|
V
|
Vanda Pharmaceuticals Inc
XBER:VM4
|
US |
Heidelberg Pharma AG
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin. The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer. For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin.
The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer.
For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
